Výsledky vyhledávání - "Mitchell E. Taub"

Mode of action and human relevance assessment of male CD-1 mouse renal adenocarcinoma associated with lifetime exposure to empagliflozin

Autor: Jonathan A. Phillips, Mitchell E. Taub, Matthew S. Bogdanffy, Jing Yuan, Brian Knight, James D. Smith, Warren W. Ku

Publikováno v: Journal of applied toxicology : JATREFERENCES. 42(10)

Inhibition of sodium-glucose cotransporter-2 (SGLT2) has been shown to be a safe and efficacious approach to support managing Type 2 diabetes. In the 2-year carcinogenicity study with the SGLT2 inhibitor empagliflozin in CD-1 mice, an increased incid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5da79d0e060b6e3ba111be8d8ebf1f5
https://pubmed.ncbi.nlm.nih.gov/35393688

Zobrazit plný text záznamu

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

Autor: Sabrina Wiebe, Ashish Sharma, Martin F. Fromm, Alen Jambrecina, Peter Stopfer, Fabian Müller, Edith Hauel, Kerstin Bader, Mitchell E. Taub, Gerd Mikus, Kathrin Hohl, Sven Schmidt-Gerets, Thomas Giessmann, Thomas Ebner, Naoki Ishiguro

Publikováno v: Clinical Pharmacokinetics

Background and Objective A novel cocktail containing four substrates of key drug transporters was previously optimized to eliminate mutual drug–drug interactions between the probes digoxin (P-glycoprotein substrate), furosemide (organic anion trans

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a1d884a334c462b41c331df14368ac
https://doi.org/10.1007/s40262-020-00907-w

Zobrazit plný text záznamu

Evaluation of Erythromycin as a Tool to Assess CYP3A Contribution of Low Clearance Compounds in a Long-Term Hepatocyte Culture

Autor: Klairynne Raymond, Tom S. Chan, Mitchell E. Taub, Young-Sun Scaringella

Publikováno v: Drug Metabolism and Disposition. 48:690-697

Long-term hepatocyte culture systems such as HepatoPac are well suited to evaluate the metabolic turnover of low clearance (CL) drugs because of their sustained metabolic capacity and longer-term viability. Erythromycin (ERY), a moderate, mechanism-b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3b577d25b8bf867b1ca9ffb3f63cc6d6
https://doi.org/10.1124/dmd.120.090951

Zobrazit plný text záznamu

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

Autor: Bhagwat Prasad, Peter Stopfer, Valerie Nock, Hannah Britz, Thorsten Lehr, Mitchell E. Taub, Éric Fernandez, Ting Wang, Nina Hanke

Publikováno v: Pharmaceutical Research

PurposeTo provide whole-body physiologically based pharmacokinetic (PBPK) models of the potent clinical organic anion transporter (OAT) inhibitor probenecid and the clinical OAT victim drug furosemide for their application in transporter-based drug-d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d97dfb895d7786ecae4afde34906ccb7
https://pubmed.ncbi.nlm.nih.gov/33237382

Zobrazit plný text záznamu

N-Methylation of BI 187004 by Thiol S-Methyltransferase

Autor: Hlaing Hlaing Maw, Aaron M Teitelbaum, Scot Campbell, Xingzhong Zeng, Mitchell E. Taub

Publikováno v: Drug Metabolism and Disposition. 46:770-778

BI 187004, an 11β-hydroxysteroid dehydrogenase 1 inhibitor, was administered once daily for 14 days to eight patients with type 2 diabetes mellitus. N-methylation was identified as a major biotransformation pathway. In four patients treated with BI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::86b191b3aa04ccefbf3466b2e097828d
https://doi.org/10.1124/dmd.117.079764

Zobrazit plný text záznamu

A Predominant Oxidative Renal Metabolite of Empagliflozin in Male Mice Is Cytotoxic in Mouse Renal Tubular Cells but not Genotoxic

Autor: Jonathan A. Phillips, Hlaing Hlaing Maw, Warren W. Ku, Hongbin Yu, Patricia A. Escobar, William T. Loging, Mitchell E. Taub, Zimei Huang, Pamela Foppiano, James D. Smith

Publikováno v: International Journal of Toxicology. 36:440-448

In a previously reported CD-1 mouse 2-year carcinogenicity study with the sodium glucose cotransporter-2 inhibitor empagliflozin, an increased incidence of renal tubular adenomas and carcinomas was identified only in the male high-dose group. Follow-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9699980ee330bbb7ff5ea19dddde0c66
https://doi.org/10.1177/1091581817735090

Zobrazit plný text záznamu

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

Autor: Kathrin Hohl, Naoki Ishiguro, Thomas Giessmann, Ashish Sharma, Arvid Jungnik, Mitchell E. Taub, Dietmar Gansser, Thomas Ebner, Peter Stopfer, Fabian Müller

Publikováno v: European Journal of Drug Metabolism and Pharmacokinetics

In a recently described probe drug cocktail for clinically relevant drug transporters containing digoxin, furosemide, metformin and rosuvastatin, mutual interactions were essentially absent except for increases in the systemic exposure of rosuvastati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afbd0bd57acd766fd3ed2edd8e0edb2c
https://doi.org/10.1007/s13318-017-0427-9

Zobrazit plný text záznamu

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

Autor: Naoki Ishiguro, Mitchell E. Taub, H Zimdahl-Gelling, Dietmar Gansser, Kathrin Hohl, Thomas Giessmann, Thomas Ebner, Ashish Sharma, M Wein, Peter Stopfer, Fabian Müller

Publikováno v: Clinical Pharmacology and Therapeutics

This article reports the clinical investigation of a probe drug cocktail containing substrates of key drug transporters. Single oral doses of 0.25 mg digoxin (P-gp), 5 mg furosemide (OAT1 and OAT3), 500 mg metformin (OCT2, MATE1, and MATE2-K), and 10

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::052f525d5dc04403b486b804b09b783a
http://europepmc.org/articles/PMC5102573

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání